Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects

tiistai 7. heinäkuuta 2026 päivittänyt: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer

The trial comprises Phase I dose escalation/expansion and Phase II combination therapy. Using a multicenter, open-label, non-randomized design, breast cancer patients will receive TQB3126 to assess its safety, tolerability, pharmacokinetics and preliminary efficacy.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

306

Vaihe

  • Vaihe 2
  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Herui Yao, Doctor
  • Puhelinnumero: +86 13500018020
  • Sähköposti: yaohrsysu@163.com

Opiskelupaikat

  • Kiina
    • Guangdong
      • Guangzhou, Guangdong, Kiina, 510288
        • Sun Yat-sen Memorial Hospital, Sun Yat-Sen University
        • Ottaa yhteyttä:
      • Meizhou, Guangdong, Kiina, 514000
        • Meizhou People's Hospital
        • Ottaa yhteyttä:
          • Jingna Wu, Doctor
          • Puhelinnumero: +86 13431819838
          • Sähköposti: 547511952@qq.com
    • Hubei
      • Wuhan, Hubei, Kiina, 430000
        • Zhongnan Hospital of Wuhan University
        • Ottaa yhteyttä:
    • Hunan
      • Changsha, Hunan, Kiina, 410000
        • The Third Xiangya Hospital of Central South University
        • Ottaa yhteyttä:
          • Jun Zhang, Doctor
          • Puhelinnumero: +86 13973131500
          • Sähköposti: 296864403@qq.com
    • Sichuan
      • Chengdu, Sichuan, Kiina, 610041
        • Sichuan Cancer Hospital
        • Ottaa yhteyttä:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kiina, 300202
        • Tianjin Medical University Cancer Institute & Hospital
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  1. Subjects voluntarily participate in this study, sign the informed consent form, and demonstrate good treatment compliance.
  2. Aged 18 to 75 years at the time of informed consent signature; Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; estimated survival expectancy of more than 3 months.
  3. Histopathologically confirmed breast cancer.
  4. Documented disease progression confirmed by clinical or imaging evidence during or after the most recent prior systemic therapy prior to the first study drug administration.
  5. Have evaluable lesions per RECIST v1.1 criteria (measurable lesions; or bone-only metastases with at least one osteolytic or mixed lesion).
  6. Adequate tissue samples shall be provided at screening for gene mutation testing to clarify genetic status.
  7. Laboratory test results meet the criteria specified in the protocol (blood routine, liver and renal function, coagulation function, cardiac ultrasound Left Ventricular Ejection Fraction(LVEF) and other indicators are all within the protocol-specified ranges).
  8. Subjects of childbearing potential must agree to use effective contraceptive measures throughout the study and for 6 months after study completion (the same requirement applies to male subjects); serum or urine pregnancy test result is negative within 7 days prior to enrollment.

Exclusion Criteria:

  1. Other malignant tumors within 5 years prior to first dose, except those cured by single surgical treatment with at least 5 years of disease-free survival, or cured differentiated thyroid cancer, cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder tumors.
  2. Conditions affecting intravenous access or blood sampling, or multiple factors affecting oral drug administration/absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction).
  3. Unresolved toxicity from prior therapy of Grade >1 (CTCAE v6.0), except Grade 2 alopecia, Grade 2 anemia, clinically insignificant laboratory abnormalities, or hypothyroidism stable on hormone replacement therapy.
  4. Major surgery, significant traumatic injury within 4 weeks before first dose, anticipated need for major surgery during the study, or long-standing unhealed fracture.
  5. Any bleeding event of Grade >=3 within 4 weeks before first dose.
  6. Arterial/venous thrombotic events within 6 months before first dose (e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism), excluding catheter-related or superficial venous thrombosis.
  7. Active viral hepatitis that is poorly controlled (Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV)-infected subjects meeting protocol-specified criteria may be enrolled).
  8. Active syphilis infection requiring treatment.
  9. Active tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or radiation pneumonitis requiring treatment, or history of/current interstitial lung disease (ILD).
  10. History of psychotropic substance abuse unable to be discontinued, mental disorders, epilepsy requiring treatment, or severe psychiatric/neurological disease.
  11. Planned or prior allogeneic bone marrow or solid organ transplantation.
  12. Decompensated cirrhosis (Child-Pugh Class B or C) or history of hepatic encephalopathy.
  13. Significant cardiovascular disease, including New York Heart Association(NYHA) Class >II heart failure, clinically significant ventricular arrhythmia, unstable angina, myocardial infarction within 12 months, markedly prolonged QT interval corrected by Fridericia's formula (QTcF), or personal/family history of congenital long QT syndrome.
  14. Poorly controlled hypertension (resting systolic BP >=160 mmHg or diastolic BP >=100 mmHg on at least 2 measurements >=24 hours apart).
  15. Active or uncontrolled serious infection (Grade >=2).
  16. Renal failure requiring hemodialysis or peritoneal dialysis; or history of/current nephrotic syndrome (except cured) or chronic nephritis.
  17. History of immunodeficiency, including HIV infection or other acquired/congenital immunodeficiency diseases.
  18. Poorly controlled autoimmune disease requiring immunosuppressants or systemic corticosteroids for immunosuppression, continued within 7 days before first dose (except low-dose corticosteroids).
  19. Clinically significant endometrial abnormalities (including hyperplasia, dysfunctional uterine bleeding, etc.).
  20. Tumor-related conditions/treatments: anti-cancer therapy within 3 weeks before first dose or still within the drug's washout period; prior local radiotherapy not meeting protocol-specified interval or target lesion requirements; use of National Medical Products Administration (NMPA)-approved proprietary Chinese medicine with anti-tumor indications within 1 week before first dose; imaging showing tumor invasion of major vessels with risk of fatal hemorrhage; uncontrolled pleural effusion/ascites/moderate-or-greater pericardial effusion requiring repeated drainage; known leptomeningeal metastasis or uncontrolled brain metastasis symptoms; severe skeletal-related events due to bone metastases.
  21. Known hypersensitivity to the study drug or its excipients.
  22. Participation in and use of another investigational anti-tumor drug within 4 weeks before first dose.
  23. Any concomitant disease or condition that, in the investigator's judgment, seriously endangers subject safety or study compliance, or any other reason making the subject unsuitable for enrollment.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: TQB3126
Administered in accordance with the protocol
Lääke: TQB3126
TQB3126 is a targeted protein degrader.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Dose Limiting Toxicity (DLT)
Aikaikkuna: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
DLT is defined as toxicities that meet pre-defined severity criteria (according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 6.0) and are assessed as related to TQB3126, occurring from the first dose to the end of the first treatment cycle.
From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
Maximum Tolerated Dose (MTD)
Aikaikkuna: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
MTD is defined as the highest dose at which DLT occurs in less than 33% of subjects.
From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
Recommended Phase II Dose (RP2D)
Aikaikkuna: Observation is expected to continue through Cycle 6 Day 28 throughout the study, around 6 months.
The dose recommended for Phase II study based on integrated safety, tolerability, pharmacokinetic and efficacy data.
Observation is expected to continue through Cycle 6 Day 28 throughout the study, around 6 months.
Adverse Events (AEs)
Aikaikkuna: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
The occurrence, incidence and severity of all adverse events (AEs).
From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
Serious Adverse Events (SAEs)
Aikaikkuna: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
The occurrence, incidence and severity of all serious adverse events (SAEs).
From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
Abnormal Incidence of Laboratory Test Indicators
Aikaikkuna: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
Incidence and severity of abnormal laboratory values.
From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
Objective Response Rate (ORR)
Aikaikkuna: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
The proportion of subjects with a best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1.
From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Peak Concentration (Cmax)
Aikaikkuna: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Maximum observed plasma concentration of TQB3126.
Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Time to Reach Maximum Plasma Concentration (Tmax)
Aikaikkuna: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Time to reach the maximum plasma concentration of TQB3126.
Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Elimination Half-life (t1/2)
Aikaikkuna: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Elimination half-life of TQB3126 after oral dosing.
Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t)
Aikaikkuna: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Area under the plasma concentration-time curve from time zero to the last measurable concentration.
Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞)
Aikaikkuna: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Area under the plasma concentration-time curve from time zero extrapolated to infinity.
Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Apparent Clearance (CL/F)
Aikaikkuna: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Apparent total clearance of TQB3126 from plasma.
Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Apparent Volume of Distribution (Vz/F)
Aikaikkuna: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Apparent volume of distribution of TQB3126 in plasma.
Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.
Clinical Benefit Rate (CBR)
Aikaikkuna: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
The proportion of subjects with a best overall response of complete response, partial response, or stable disease lasting a pre-specified minimum duration, per RECIST v1.1.
From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
Disease Control Rate (DCR)
Aikaikkuna: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
The proportion of subjects with a best overall response of complete response, partial response, or stable disease, per RECIST v1.1.
From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
Duration of Response (DOR)
Aikaikkuna: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
The time from the first documentation of complete or partial response to the first documentation of disease progression.
From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
Progression-Free Survival (PFS)
Aikaikkuna: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
The time from the first dose to the first documentation of disease progression or death from any cause, whichever occurs first.
From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
Time to Response (TTR)
Aikaikkuna: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
The time from the first dose to the first documentation of complete or partial response.
From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Lauantai 1. elokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Keskiviikko 1. elokuuta 2029

Opintojen valmistuminen (Arvioitu)

Torstai 1. elokuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 7. heinäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 7. heinäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 13. heinäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 13. heinäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 7. heinäkuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. huhtikuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • TQB3126-I/II-01

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Kliiniset tutkimukset Rintasyöpä

Hae vastaavia kokeiluja

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

CROs by country

CROs in Mongolia

Ehdot

Harvinaiset sairaudet

Huumeiden interventiot

Ravintolisät

Sponsori / yhteistyökumppanit

Sijainnit

3
Tilaa